Price Alert

Castle Biosciences Inc. (CSTL)

NASDAQ: CSTL · Real-Time Price · USD

19.82

0.41 (2.11%)

At close: Aug 14, 2025, 3:59 PM

19.82

-0.03%

Pre-market: Aug 15, 2025, 08:45 AM EDT

Castle Biosciences Statistics

Share Statistics

Castle Biosciences has 29.01M shares outstanding. The number of shares has increased by 4.09% in one year.

Shares Outstanding	29.01M
Shares Change (YoY)	4.09%
Shares Change (QoQ)	1.26%
Owned by Institutions (%)	90.43%
Shares Floating	28.1M
Failed to Deliver (FTD) Shares	46
FTD / Avg. Volume	0.01%

Short Selling Information

The latest short interest is 1.41M, so 4.9% of the outstanding shares have been sold short.

Short Interest	1.41M
Short % of Shares Out	4.9%
Short % of Float	5.61%
Short Ratio (days to cover)	4.26

Valuation Ratios

The PE ratio is 40.57 and the forward PE ratio is -10.25. Castle Biosciences's PEG ratio is -0.31.

PE Ratio	40.57
Forward PE	-10.25
PS Ratio	2.23
Forward PS	1.8
PB Ratio	1.62
P/FCF Ratio	20.26
PEG Ratio	-0.31

Financial Ratio History

Enterprise Valuation

Castle Biosciences has an Enterprise Value (EV) of 646.87M.

EV / Sales	1.95
EV / EBITDA	16.96
EV / EBIT	9.97
EV / FCF	17.7

Financial Position

The company has a current ratio of 7.29, with a Debt / Equity ratio of 0.06.

Current Ratio	7.29
Quick Ratio	7.13
Debt / Equity	0.06
Debt / EBITDA	0.69
Debt / FCF	0.72
Interest Coverage	15.03

Financial Efficiency

Return on Equity is 4% and Return on Invested Capital is 1.52%.

Return on Equity	4%
Return on Assets	3.43%
Return on Invested Capital	1.52%
Revenue Per Employee	$423.56K
Profits Per Employee	$23.27K
Employee Count	784
Asset Turnover	0.63
Inventory Turnover	7.4

Taxes

Income Tax	3.32M
Effective Tax Rate	15.39%

Stock Price Statistics

The stock price has increased by -28.49% in the last 52 weeks. The beta is 1.09, so Castle Biosciences's price volatility has been higher than the market average.

Beta	1.09
52-Week Price Change	-28.49%
50-Day Moving Average	18.15
200-Day Moving Average	23.29
Relative Strength Index (RSI)	58.66
Average Volume (20 Days)	462,287

Income Statement

In the last 12 months, Castle Biosciences had revenue of 332.07M and earned 18.25M in profits. Earnings per share was 0.66.

Revenue	332.07M
Gross Profit	271.86M
Operating Income	8.67M
Net Income	18.25M
EBITDA	38.14M
EBIT	22.14M
Earnings Per Share (EPS)	0.66

Full Income Statement

Balance Sheet

The company has 119.71M in cash and 26.34M in debt, giving a net cash position of 93.36M.

Cash & Cash Equivalents	119.71M
Total Debt	26.34M
Net Cash	93.36M
Retained Earnings	-200.13M
Total Assets	544.73M
Working Capital	297.78M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 64.87M and capital expenditures -28.33M, giving a free cash flow of 36.54M.

Operating Cash Flow	64.87M
Capital Expenditures	-28.33M
Free Cash Flow	36.54M
FCF Per Share	1.32

Full Cash Flow Statement

Margins

Gross margin is 81.87%, with operating and profit margins of 2.61% and 5.49%.

Gross Margin	81.87%
Operating Margin	2.61%
Pretax Margin	6.49%
Profit Margin	5.49%
EBITDA Margin	11.48%
EBIT Margin	2.61%
FCF Margin	11%

Dividends & Yields

CSTL does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	2.46%
FCF Yield	4.94%

Dividend Details

Analyst Forecast

The average price target for CSTL is $37, which is 93.4% higher than the current price. The consensus rating is "Buy".

Price Target	$37
Price Target Difference	93.4%
Analyst Consensus	Buy
Analyst Count	7

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	15.57
Graham Upside	-18.61%

Scores

Altman Z-Score	4.44
Piotroski F-Score	3